National Bank of Canada
LRMR icon

National Bank of Canada’s Larimar Therapeutics LRMR Stock Holding History

National Bank of Canada’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$13 – 3091
2024
Q3 		$13 Buy
+2
New +$16 ﹤0.01% 2678

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

National Bank of Canada's LRMR Position: Q4 2024 in Review

National Bank of Canada sold out of Larimar Therapeutics (LRMR) in Q4 2024, closing a stake of 2 shares — an estimated $13 sold.

National Bank of Canada first reported a position in LRMR in Q3 2024 and held it in 1 quarter. The position peaked at $13 in Q3 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q4 2024.

  • National Bank of Canada reported no remaining Larimar Therapeutics position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 2 Larimar Therapeutics shares in Q4 2024, an estimated $13.
  • National Bank of Canada first reported a position in Larimar Therapeutics in Q3 2024 and held it in 1 quarter.
  • National Bank of Canada's Larimar Therapeutics position peaked at $13 in Q3 2024.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.